Document Detail


Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
MedLine Citation:
PMID:  21143166     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia. Prevalence and incidence rates are rising with the advancing population age. A severe complication of untreated AF is thrombus formation in the left atrial appendage with consecutive peripheral thromboembolism. Thus, AF is a major contributor to thromboembolic events, especially in the elderly. Depending on the CHADS2 score for thromboembolic events that takes into account congestive heart failure, hypertension, age, diabetes mellitus and stroke as risk factors, oral anticoagulation therapy with vitamin K antagonists is currently the treatment of choice for the prevention of thromboembolism. However, due to drawbacks of current anticoagulation therapy new substances for oral anticoagulation therapy are currently evaluated in various clinical studies. This article provides an up to date overview of orally active compounds for the future treatment of AF. Emphasis lies on comparison of direct thrombin inhibitors with factor Xa inhibitors that are currently investigated in clinical phase III studies for the treatment of non-valvular AF. The direct thrombin inhibitor dabigatran will be compared with factor Xa inhibitors like rivaroxaban and apixaban. Other promising agents currently investigated in phase II trials such as direct factor Xa inhibitors DU-176b (edoxaban) and YM150, will also be discussed.
Authors:
Oliver Wolfram; Matthias Hammwoehner; Felix Gramley; Andreas Goette
Related Documents :
11265866 - Right heart failure: best treated by avoidance.
8110056 - Mechanical circulatory support for postcardiotomy ventricular failure: the heart instit...
18071846 - Domestic and foreign trends in the prevalence of heart failure and the necessity of nex...
9360156 - Clinical evaluation of the heartpak. a new pneumatic portable driver for use with the h...
22980066 - Significance of force transfer in mitral valve-left ventricular interaction: in vivo a...
9014806 - Wide complex tachycardia with atrioventricular dissociation and qrs morphology identica...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2010-12-14
Journal Detail:
Title:  Current vascular pharmacology     Volume:  -     ISSN:  1875-6212     ISO Abbreviation:  -     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Division of Cardiology, University Hospital, Magdeburg, Germany. andreas.goette@med.ovgu.de.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Smoking and hypertension: independent or additive effects to determining vascular damage?
Next Document:  Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial ...